<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490061</url>
  </required_header>
  <id_info>
    <org_study_id>ENT0020</org_study_id>
    <secondary_id>97864</secondary_id>
    <secondary_id>LAP #109855</secondary_id>
    <secondary_id>8857</secondary_id>
    <nct_id>NCT00490061</nct_id>
  </id_info>
  <brief_title>Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy</brief_title>
  <official_title>A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quynh-Thu Le</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
      cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
      efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
      (TTP) in this group of patients. In addition, we will determine the 2-year locoregional
      control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
      patients. We will also evaluate the profile and frequency of late toxicity, specifically
      mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
      locally advanced head and neck squamous cell carcinoma (HNSCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is substantial data to suggest that EGFR and Her-2/neu expressions are important
      predictors for prognosis in HNSCC. EGFR blockade with a monoclonal antibody in conjunction
      with radiotherapy has been shown to improve survival over radiotherapy alone in patients with
      locally advanced HNSCC. Dual inhibition of EGFR and ErbB2 tyrosine kinases results in greater
      inhibitory effect of the downstream signaling pathways in cancer cells than inhibition of
      either receptor alone. Phase I studies in HNSCC suggested that the drug is well tolerated
      when delivered either alone or concurrently with cisplatin based chemoradiotherapy in HNSCC.

      We propose to combine lapatinib with RT alone in patients with locally advanced HNSCC who
      cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of
      combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this
      group of patients. In addition, we will determine the 2-year locoregional control rate (LRC),
      progression-free survival (PFS) and overall survival (OS) in these patients. We will also
      evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic
      toxicity, of the combination of lapatinib and RT in patients with locally advanced HNSCC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 year PFS: PFS at 2 yrs after study enrollment</time_frame>
    <description>To determine the efficacy of combining lapatinib and radiotherapy in terms of Progression-free survival (PFS) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy.
Progression-free survival is defined is the time from starting treatment to the time of first documented tumor progression or death due to any cause, which ever occurs first.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST V1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival.</measure>
    <time_frame>Two years survival rate after study enrollment</time_frame>
    <description>Overall survival is the time from starting treatment until death due to any cause. For subjects who do not die, time to death will be censored at the time of last contact.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Head and Neck Cancers</condition>
  <arm_group>
    <arm_group_label>Radiotherapy and Lapatinib with DCE-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1500 mg po daily orally</description>
    <arm_group_label>Radiotherapy and Lapatinib with DCE-MRI</arm_group_label>
    <other_name>Tykerb/Tyverb</other_name>
    <other_name>GlaxoSmithKline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy (radiation)</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Radiotherapy and Lapatinib with DCE-MRI</arm_group_label>
    <other_name>IMRT - Intensity Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G.E. Healthcare 1.5T MR, systems revision 12.0 M5</intervention_name>
    <description>Standard of Care, used to deliver IMRT</description>
    <arm_group_label>Radiotherapy and Lapatinib with DCE-MRI</arm_group_label>
    <other_name>G.E. Healthcare MRI Device and Software</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCE-MRI</intervention_name>
    <description>A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.</description>
    <arm_group_label>Radiotherapy and Lapatinib with DCE-MRI</arm_group_label>
    <other_name>Dynamic contrast-enhanced magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown
             primary sites are allowed)

          -  No evidence of distant metastasis

          -  No prior radiation therapy to the head and neck sites.

          -  Able to sign a study-specific informed consent form.

          -  Women of childbearing potential and men with partners capable of producing offspring
             must be willing to practice acceptable methods of birth control to prevent pregnancy.

          -  Left ventricular ejection fraction (LVEF) within the institutional normal range as
             measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is
             not conclusive to evaluate LVEF, then a MUGA scan should be performed).

          -  Having one of the following parameters that would preclude the use of concurrent CRT:

               -  ECOG PS &gt; 2.

               -  Creatinine &gt; 1.3 or calculate or measure creatinine clearance &lt; 60 ml/min.

               -  AST or ALT &gt; 1.5 times normal limit but &lt; 3 times normal limit

               -  Total bilirubin &gt; 1.5 mg/dL but &lt; 3mg/dL

               -  History of hearing loss that would preclude cisplatin chemotherapy. These would
                  include the existing need of a hearing aid or a &gt;= 25 decibel shift over 2
                  contiguous frequencies on a pretreatment hearing test.

               -  Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy

               -  Refuse or cannot tolerate chemotherapy

          -  Age 18 years or older

        Exclusion Criteria:

          -  Known hypersensitivity to lapatinib or any of the excipients of this product
             (quinazolines).

          -  Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC
             diagnosis and treatment.

          -  History of myocardial infarction &lt; 6 months from study entry.

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.

          -  Prior treatment with EGFR or Her2/Neu directed therapies.

          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with Lapatinib.

          -  Absolute neutrophil count &lt; 1500/uL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quynh-Thu Le</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>November 11, 2016</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Quynh-Thu Le</investigator_full_name>
    <investigator_title>Professor Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place in a radiation oncology clinic, in a private room. The recruitment period spanned from 7/26/2007-11/18/2011.</recruitment_details>
      <pre_assignment_details># of subjects were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Radiotherapy (Radiation) and Lapatinib</title>
          <description>Lapatinib, 1500mg once daily, was administered for 7 days prior to, and for the duration of Intensity Modulated Radio Therapy (IMRT), delivered by G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiotherapy (Radiation) and Lapatinib</title>
          <description>1500mg/d once daily oral lapatinib administration plus Intensity Modulated Radio Therapy (IMRT) delivered by G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
Lapatinib: 1500 mg po daily orally
Radiotherapy (radiation): Standard of Care
G.E. Healthcare 1.5T MR, systems revision 12.0 M5: Standard of Care, used to deliver IMRT
PET/CT: A subset of patients received imaging before and after treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>To determine the efficacy of combining lapatinib and radiotherapy in terms of Progression-free survival (PFS) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy.
Progression-free survival is defined is the time from starting treatment to the time of first documented tumor progression or death due to any cause, which ever occurs first.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST V1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>2 year PFS: PFS at 2 yrs after study enrollment</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy (Radiation) and Lapatinib</title>
            <description>Lapatinib, 1500mg once daily, was administered for 7 days prior to, and for the duration of Intensity Modulated Radio Therapy (IMRT), delivered by G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>To determine the efficacy of combining lapatinib and radiotherapy in terms of Progression-free survival (PFS) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy.
Progression-free survival is defined is the time from starting treatment to the time of first documented tumor progression or death due to any cause, which ever occurs first.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST V1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" lower_limit="47" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival.</title>
        <description>Overall survival is the time from starting treatment until death due to any cause. For subjects who do not die, time to death will be censored at the time of last contact.</description>
        <time_frame>Two years survival rate after study enrollment</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy (Radiation) and Lapatinib</title>
            <description>Lapatinib, 1500mg once daily, was administered for 7 days prior to, and for the duration of Intensity Modulated Radio Therapy (IMRT), delivered by G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival.</title>
          <description>Overall survival is the time from starting treatment until death due to any cause. For subjects who do not die, time to death will be censored at the time of last contact.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>acute and late AE assessed at follow up appointments</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiotherapy (Radiation) and Lapatinib</title>
          <description>Lapatinib, 1500mg once daily, was administered for 7 days prior to, and for the duration of Intensity Modulated Radio Therapy (IMRT), delivered by G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>Drug (baraclude) induced hemolytic anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Lymphocyte count decreased.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT Increased</sub_title>
                <description>Alanine aminotransferase increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatermia</sub_title>
                <description>Low concentration of sodium in the blood.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE V 3.0">Edema, larynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <description>Bilateral pulmonary emboli</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>frequent and watery bowel movements</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <description>Elevated alanine aminotransferase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <description>Elevated aspartate aminotansferase</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated ALK</sub_title>
                <description>Elevated Alkaline phosphatase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>excessive loss of water</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Low concentrations of sodium in the blood</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to low accrual, this study was terminated prior to reaching 60 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Quynh Le</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-498-5032 ext 6506370734</phone>
      <email>qle@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

